أرسل هذا في رسالة قصيرة: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

  ______    _____     ____      _____    _    _   
 /_____//  |  ___||  |  _ \\   |  ___|| | |  | || 
 `____ `   | ||__    | |_| ||  | ||__   | |/\| || 
 /___//    | ||__    | .  //   | ||__   |  /\  || 
 `__ `     |_____||  |_|\_\\   |_____|| |_// \_|| 
 /_//      `-----`   `-` --`   `-----`  `-`   `-` 
 `-`